Diseases| Regentime

Mesenchymal stem cell therapy for refractory scleroderma: A report of 2 cases

ABSTRACT

Published: 27 Sep 2016
Nullam euismod commodo

We treated 2 patients with progressive, refractory scleroderma with a combined immunotherapy approach using plasmapheresis followed by rituximab and then intravenous umbilical-cord-derived allogeneic mesenchymal stem cells (MSCs). Both patients improved subjectively and objectively for over a year. Upon recurrence of their symptoms, the patients were treated again with allogeneic MSCs alone with a very good response. The combination was well tolerated and effective suggesting a large scale study may be warranted in progressive, refractory Scleroderma.

Copyrights © 2017: Regentime - Designed and Developed by Praxier (A Clyto Access Company)